Published on 22/12/2025
Strategies to Minimize Travel Burden in Rare Disease Clinical Trials
Why Travel Is a Barrier in Rare Disease Research
In rare disease clinical trials, eligible patients often reside far from trial sites, which are typically concentrated in major cities or academic centers. Given the small and globally dispersed patient populations, it’s not uncommon for participants to travel hundreds or even thousands of kilometers to access a site. This travel burden can discourage enrollment, increase dropout risk, and disproportionately exclude rural or low-income participants.
Moreover, many rare disease patients are children, elderly, or have mobility challenges that make long-distance travel physically, emotionally, and financially taxing. Recognizing and addressing this barrier is essential to achieving equitable and successful clinical trial participation.
Key Travel-Related Challenges in Rare Disease Trials
Participants and their caregivers may encounter several obstacles related to travel, including:
- Geographic Isolation: Trial sites may be located in only a handful of countries, requiring international travel for some participants.
- Financial Constraints: Costs associated with airfare, lodging, meals, and local transport can be prohibitive, especially for multi-visit studies.
- Medical Fragility: Many patients are immunocompromised, wheelchair-bound, or dependent on caregivers, making travel risky and complex.
- Visa and Documentation Delays: Cross-border travel introduces
Left unaddressed, these burdens compromise both trial diversity and scientific integrity.
Implementing Site-to-Patient (S2P) Trial Models
One of the most effective ways to reduce travel burden is through decentralized or hybrid trial models that bring the study to the patient. Components of S2P models include:
- Home Health Visits: Trained nurses conduct assessments, sample collection, and safety checks at the patient’s home.
- Telemedicine Visits: Video-based investigator check-ins reduce the need for in-person site visits.
- Mobile Sites: Use of vans or portable equipment for conducting local procedures in rural settings.
- Local Lab Partnerships: Leveraging nearby diagnostics facilities for routine tests and sample shipments.
These approaches can be implemented selectively based on study phase, complexity, and patient condition.
Travel Logistics and Reimbursement Programs
When travel is unavoidable, sponsors must provide comprehensive support to ensure participants can attend without financial strain. Best practices include:
- Centralized Travel Coordination: Provide patients with a dedicated travel concierge to manage booking, itineraries, and special needs (e.g., wheelchair-accessible transport).
- Advance Reimbursement: Offer pre-paid travel cards or upfront disbursements to avoid out-of-pocket expenses.
- Lodging Support: Partner with hotels near sites that accommodate patient-specific needs.
- Caregiver Stipends: Include caregiver travel costs and per diems as part of trial budgeting.
These services reduce dropout due to travel stress and demonstrate respect for patient time and resources.
Case Study: Multi-Country Trial Using Decentralized Visits
In a global rare epilepsy trial, the sponsor implemented decentralized visits for long-term follow-up. Patients in Canada, Brazil, and Eastern Europe were offered the choice between on-site and home-based visits.
Outcomes included:
- 35% of participants opted for hybrid participation (some on-site, some remote)
- Travel-related withdrawal dropped by 60% from previous trials
- Enrollment increased in rural provinces with previously zero participation
This example shows that travel flexibility leads to more diverse and engaged trial populations.
Leveraging Local Partnerships for Patient Support
Partnering with community healthcare providers, rare disease clinics, and patient organizations can help reduce the need for long-distance travel. These partners can:
- Perform routine procedures closer to the patient’s home
- Assist with medication delivery or IV administration
- Offer emotional and logistical support to caregivers
- Act as trusted liaisons between patients and trial teams
Engaging local resources can expand trial reach and reduce the site burden simultaneously.
Technology Solutions to Support Remote Participation
Digital tools help bridge the gap between sites and remote participants:
- ePRO Apps: Allow patients to submit data without site visits.
- Telehealth Platforms: Enable secure, compliant video assessments with investigators.
- Remote Monitoring Devices: Wearables collect real-time data on vitals, movement, or sleep patterns.
- Virtual Site Portals: Provide access to visit schedules, trial education materials, and direct communication with coordinators.
These tools empower patients and reduce physical demands while maintaining data quality and compliance.
Regulatory Considerations and Risk Mitigation
Reducing travel burden must be balanced with regulatory compliance and patient safety. Sponsors should:
- Submit protocol amendments when shifting to remote models
- Ensure local IRBs approve travel support and reimbursement programs
- Use Good Clinical Practice (GCP)-trained home health providers
- Maintain documentation of decentralized procedures for audits
Proper documentation and oversight are essential to ensure decentralization enhances rather than compromises trial quality.
Conclusion: Reducing Burden, Increasing Access
Travel should never be the reason a patient misses the opportunity to participate in a potentially life-changing clinical trial—especially in the rare disease space where every participant matters. Sponsors and CROs must proactively design travel-inclusive and travel-flexible studies that empower, not exclude, patients.
By reducing physical and financial burdens, engaging local partners, and embracing decentralized tools, the rare disease community can move toward more equitable, accessible, and patient-centered clinical research.